We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




CACLP 2025 New Date and Venue Announced

By LabMedica International staff writers
Posted on 16 Oct 2024

The 22nd China International In Vitro Diagnostic Expo, organized by the China Association of Clinical Laboratory Practice Expo (CACLP, Shanghai, China), is set to take place from March 21 to 24, 2025, in Hangzhou, China. More...

Following the impressive numbers recorded by CACLP 2024, the upcoming event will return to provide global participants with a convenient and enriching experience at the newly inaugurated Hangzhou Grand Convention & Exhibition Center.

Situated in the economically dynamic Yangtze River Delta, Hangzhou boasts convenient transportation, advanced innovation, and a wealth of natural and cultural resources. This charming city creates an ideal environment for the in vitro diagnostic (IVD) industry. Hangzhou has 6,626 medical and healthcare institutions, which include 414 hospitals and 27 top-tier (Grade A, Level 3) hospitals. Moreover, Hangzhou has established China’s first dedicated IVD industry promotion institute to support local industry development. With China’s favorable visa-free policy, international participants will find it easier than ever to attend and explore an optimal setting for collaboration, networking, and the latest market trends and innovations.

CACLP 2024 was a remarkable success, showcasing a wide range of products and technologies from participants. The event, which took place in March 2024, attracted 1,346 exhibitors and 42,751 visitors from China and 40 other countries, all gathered in a vast area of 130,000 square meters. A series of academic activities featured 125 scientific lectures presented by 315 academic speakers, drawing over 5,000 delegates. These activities received 462,150 online views via CACLP's WeChat channels and app.

Following the success of CACLP 2024, numerous professionals across the IVD industry are expected to participate in the concurrent academic activities during CACLP 2025. These include the 10th China Experimental Medicine Conference (CEMC) and series sessions, as well as the 12th China IVD Industry Development Conference (CIIDC) and series forums. These activities will encompass in-depth discussions on current hot topics in laboratory medicine and IVD, with renowned experts and scholars presenting cutting-edge research findings, while industry leaders share valuable experiences.

Related Links:
CACLP


Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Nutating Mixer
Enduro MiniMix
New
Blood Culture Control Panel
Gram-Negative Blood Culture Control Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.